Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-11-28
2011-10-18
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S001610, C424S646000
Reexamination Certificate
active
08038999
ABSTRACT:
A method of treating breast cancer that is at least partially ER+is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.
REFERENCES:
patent: 4393071 (1983-07-01), Fujii et al.
patent: 4683200 (1987-07-01), Hirohashi et al.
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 5075425 (1991-12-01), Kotitschke et al.
patent: 5135849 (1992-08-01), Soto
patent: 6200547 (2001-03-01), Volkonsky et al.
patent: 2002/0006630 (2002-01-01), Sirbasku
patent: 0246734 (1987-11-01), None
patent: 0702960 (1996-03-01), None
patent: WO 9213563 (1992-08-01), None
patent: WO 9640108 (1996-12-01), None
patent: 99/33869 (1999-07-01), None
Sato (Nippon Gan Chiryo Gakkaishi 28(10):1716-1723 (1993).
Reddel et al (Exp. Cell Research 161:277-284 (1985)).
Wang et al. (Anticancer Research 19:445-450 (1999)).
Jiang et al (Anticancer Research 22:2685-2692 (2002)).
Mathias et al (J. Nuclear Medicine 37(6):1003-1008 (1996).
Murphy (The Oncologist 3:129-130 (1998).
Patel et al. (Proc. Nat'l. Acad. Sci. 80:6518-6522 (1983).
Feng et al. (Journal Dairy Science 78:2352-2357 (1995).
Hallaway et al (Proc. Nat'l. Acad. Sci. 85:10108-10112 (1989).
Larson et al (J. Nat'l. Cancer Inst. 64(1): 41-53 (1980).
Kresse et al (Magnetic Resonance in Medicine 40(2):236-242 (1998).
Schirner et al. (J. Can. Res. Clin. Oncol. 121: Suppl. 1, A2 Jan. 1995; Abstract).
Danielpour et al., In Vitro Cell. & Dev. Biol. Jan. 1988, 24, pp. 42-52.
Parisot et al., British Journal of Cancer, 1999, vol. 79(5/6), pp. 693-700.
Deture et al., A Comparison of Serum Immunoglobulins From Patients With Non-Neoplastic Prostates and Prostatic Carcinoma, The Journal of Urology, Oct. 1978, pp. 435-437, vol. 120.
O'Boyle et al., Immunization of Colorectal Cancer Patients with Modified Ovine Submaxillary Gland Mucin and Adjuvants Induces IgM and IgG Antibodies to Sialylated Tn, Cancer Research, Oct. 15, 1992, pp. 5663-5667, vol. 52.
Schauenstein et al., Selective Decrease in Serum Immunoglobulin G1, American Cancer Society, Aug. 1, 1996, pp. 511-516, vol. 78, Issue No. 3.
Patent Application Search Report date mailed Mar. 3, 2006 from European Patent Application No. 02780675.1-2123.
Furuya et al (Cancer Research, Dec. 1989, vol. 49, pp. 6670-6674).
Hoffman (‘The Biochemistry of Clinical Medicine’, 1970, pp. 48 and 55).
European Search Report Dated Feb. 2, 2011.
European Search Report Dated Feb. 4, 2011.
Karmanos Cancer Center website search (“MCF-7”; Apr, 20, 2010; pp. 1-2).
Kemp et al, Effects of Anti-Transferrin Receptor Antibodies on the Growth of Neoplastic Cells, Pathobiology, Karger, Basel, CH, vol. 60, No. 1, Jan. 1, 1992, pp. 27-32.
Kontoghiorghes et al, Site Specificity of Iron Removal From Transferrin by Alpha-Keohydroxypyridine Chelators, Febs Letters, Elsevier, Ambsterdam, NL, vol. 189, No. 1, Sep. 9, 1985, pp. 141-144.
Yang et al., An Antisense Transferrin Receptor Oligonucleotide Suppresses Gene Expression and Proliferation in Human Breast Cancer Cell Lines; Proceedings of the 89th Annual Meeting of The American Asociation for Cancer Research, New Orleans, LA, Mar. 28-Apr. 1, 1988, vol. 39, p. 417/418.
Yang et al., Antisense Transferrin Receptor Oligonucleotide Induces Apoptosis in Human MCF-7 Breat Carcinoma Cells; Proceedings of the Annual Meeting of The American Association for Cancer Research, vol. 41, Mar. 1, 2000, p. 752 .
Yang et al., Expression of Transferrin Receptor and Ferritin H-Chain MRNA Are Associated with Clinical and Histopathological Prognostic Indicators in Breast Cancer, International Institute of Anticancer Research, vol. 21, No. 1B, Jan. 1, 2001, pp. 541-550.
Bristol Lynn
Merchant & Gould P.C.
LandOfFree
Breast cancer eradication program does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Breast cancer eradication program, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer eradication program will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4273159